focus -WSS

focus

author：fashion 2025-09-27 19:29:12 - browse：63455

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FTC loses bid to block Novant's North Carolina hospital merger

hotspot

WSS

Inequities make cancer less preventable for women: report

WHO recommends dropping component of many flu vaccines

Stopping antidepressants leads to symptoms for 1 in 6 patients

Eli Lilly’s Zepbound improved liver scarring in mid

Would Medicare drug price negotiations stall in a shutdown?

FDA approves Moderna’s RSV vaccine, its second licensed product

explore

focus

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Stopping antidepressants leads to symptoms for 1 in 6 patients

Medicare proposal to cover medical devices draws a mixed reaction

Elevance PBM president out as customers face prescription chaos

Malaria cases in Florida and Texas: Here’s what you need to know

Medicaid, Medicare dual

Walensky prepares to leave CDC — and Congress — behind

CMS got Medicare Advantage quality rating wrong, judge rules

Heart attack and stroke risk calculators need revising

FDA approves Moderna’s RSV vaccine, its second licensed product

hotspot

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Mindstrong's demise and the future of mental health care

Health tech startups drop sharply from 2021 highs

Data show record exodus of life scientists from academia

Mindstrong's demise and the future of mental health care

For pregnant people, addiction treatment shouldn't mean a call to child protective services

explore

hotspot

hotspot

explore